# Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial

Study · id `cardio:ct-nct06007222` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06007222](<https://clinicaltrials.gov/study/NCT06007222>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06007222

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT06007222. Randomized; no masking; primary purpose treatment. Start 2023-04-06 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT06007222, source copy `cardio:ctgov-nct06007222-2024-09-23`, retrieved 2026-10-26)
- Started: 2023-04-06 (actual) (ClinicalTrials.gov record NCT06007222, source copy `cardio:ctgov-nct06007222-2024-09-23`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06007222, source copy `cardio:ctgov-nct06007222-2024-09-23`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06007222, source copy `cardio:ctgov-nct06007222-2024-09-23`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT06007222, source copy `cardio:ctgov-nct06007222-2024-09-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06007222-2024-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
- Condition: Aortic Stenosis
- Condition: TAVI(Transcatheter Aortic Valve Implantation)
- Condition: Aspirin
- Condition: DAPT(Dual Antiplatelet Therapy)
- Condition: SAPT(Single Antiplatelet Therapy)
- Intervention (Drug): Aspirin group
- Intervention (Drug): Non-antithrombotic group
- Lead sponsor: OCEAN-SHD Study Group
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 9c3dff843bbcbed9df2cc0962bcef13be0d7a1b8e4ffbc0a90acad5bba09b47f
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
